Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Texas
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Texas
69 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi di Texas.
Kota di Texas
- Houston47 studi
- San Antonio22 studi
- Dallas20 studi
- Austin8 studi
- Tyler6 studi
- Irving6 studi
- Fort Worth5 studi
- League City4 studi
- The Woodlands3 studi
Teks studi resmi (Bahasa Inggris)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site#0102, Houston
- Site #0152, Waco
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06788990A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- dan 2 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- dan 3 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07090499A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 5, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07085091Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05877599A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- UT Southwestern Medical Center, Dallas
- Texas Oncology - San Antonio, Fredericksburg
- MD Anderson Cancer Center, Houston
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07276399Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07339176Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05267626A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- MD Anderson Cancer Center, Houston
- START Center for Cancer Research, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- dan 1 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- NEXT Oncology Austin, Austin
- NEXT Oncology - Dallas, Irving
- NEXT Oncology - San Antonio, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06657222A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- MD Anderson Cancer Center, Houston
- Site 102 - START San Antonio, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07462377ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06597721A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Site US074, Tyler
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07807163A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- START Dallas Forth Worth, Fort Worth
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07602842FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- M. D. Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07216105Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06084481A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Joe Arrington Cancer Research & Treatment Center, Lubbock
- Renovatio Clinical, The Woodlands
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07115043A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- Next Oncology Dallas /ID# 276659, Irving
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07241039A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Dallas
- Normunity Investigational Site, Houston
- Normunity Investigational Site, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Houston Methodist Hospital, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04895709Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- MD Anderson in The Woodlands, Conroe
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Michael E DeBakey VA Medical Center, Houston
- dan 4 lainnya
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04333537Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START San Antonio, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT05985655SMP-3124LP in Adults With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06526819A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT062424703-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
- M D Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT05674396A Study of DM005 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06515990A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Texas Oncology, Dallas
- Oncology Consultants, Houston
- Texas Oncology, Tyler
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT03526835Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- dan 8 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
- dan 5 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- START, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT06993844Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.